Life sciences

Even the largest pharma companies will need to step outside their sector and collaborate with other organisations, according to new research by PwC.

It’s no great revelation that the biotech funding model is broken, yet the market for the industry’s drugs has never been greater. So where is the fix, asks Nuala Moran.

With investors keeping their money in their pockets, and the IPO window nailed shut, the 33 year-old model of biotech funding is outdated, says a new report.

Helsinn Holding SA, a privately-owned pharmaceutical company, is to establish a centre of excellence in R&D of oral solid dosage at its existing site in Dublin.

A national centre for sequencing plant, animal and microbial genomes is to be set up by the UK’s Biotechnology and Biological Sciences Research Council.

Three of the UK’s largest learned societies in biological and environmental sciences have signed an agreement which is a significant step towards integration.

With investment in listed companies down by 98 per cent – and still falling – France's biotech trade association is asking for help.

Everyone’s strapped for cash – except pharma. But the latest spending spree is no more of a fix for expiring patents than botox is for ageing skin, writes Nuala Moran.